Rate Video

ESMO 2018 | Rob Jones reviews: GU Cancer data from ESMO

Bladder Cancer Genitourinary Cancer Kidney Cancer Prostate Cancer Avelumab Axitinib Checkpoint Inhibitors Pembrolizumab Rucaparib

JAVELIN Renal 101 KEYNOTE-057 TRITON2

Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses exciting genitourinary cancer trial data from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. He highlights the KEYNOTE-057 (NCT02625961) trial looking at the efficacy of pembrolizumab in high-risk non-muscle-invasive bladder cancer that is unresponsive to BCG; the TRITON2 trial (NCT02952534) of the PARP inhibitor rucaparib in metastatic castration resistant prostate cancer; and the JAVELIN Renal 101 study (NCT02684006) investigating avelumab plus axitinib for advanced renal cell cancer.

SAPROCAN: saracatinib and docetaxel for mCRPC

Robert Jones • 15 Feb 2021

What does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?

Robert Jones • 8 Feb 2018

Promising POUT: perioperative chemotherapy for upper tract urothelial cancer

Robert Jones • 8 Feb 2018

Prostate cancer update: practice-changing data?

Related Videos

ABACUS trial: preoperative atezolizumab in urothelial carcinoma

How to involve patients in clinical decision making

Developing a self-management programme to support prostate and testicular cancer survivors

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors